Syncona Shs GBP (GB:SYNC) has released an update.
Syncona Limited’s portfolio company Spur Therapeutics has revealed promising results from its Phase I/II GALILEO-1 study of FLT201, a novel gene therapy candidate for Gaucher disease. The data showcased at the ESGCT Congress in Rome highlights significant reductions in lyso-Gb1 levels and improvements in bone marrow burden, indicating FLT201’s potential to surpass existing treatments as a new standard of care. With a favorable safety profile and plans for a Phase III trial in 2025, this development marks a significant advancement in Gaucher disease treatment.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
